Alpha-antitrypsin - PPL Therapeutics

Drug Profile

Alpha-antitrypsin - PPL Therapeutics

Alternative Names: AAT - PPL Therapeutics; Alpha-1 proteinase inhibitor - PPL Therapeutics; Alpha-1-antitrypsin - PPL Therapeutics; rAAT - PPL Therapeutics; recAAT - PPL Therapeutics; Recombinant AAT; TgAAT - PPL Therapeutics

Latest Information Update: 22 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PPL Therapeutics PLC
  • Developer Bayer; PPL Therapeutics PLC
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Leucocyte elastase inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Alpha 1-antitrypsin deficiency; Cystic fibrosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jul 2003 Suspended - Clinical-Phase-Unknown for Alpha 1-antitrypsin deficiency in United Kingdom (IV)
  • 10 Jul 2003 Suspended - Phase-II for Alpha 1-antitrypsin deficiency in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top